Vertex's Orkambi nabs FDA approval but may face payer backlash

Vertex's Orkambi nabs FDA approval but may face payer backlash

The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.

Five things for pharma marketers to know: Monday, July 6

Five things for pharma marketers to know: Monday, July 6

Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

Sermo expands to Canada in global expansion

Sermo expands to Canada in global expansion

The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.

Pharmacy groups urge consistent naming of biosimilars

Pharmacy groups urge consistent naming of biosimilars

The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.

Five things for pharma marketers to know: Wednesday, July 1

Five things for pharma marketers to know: Wednesday, July 1

Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Five things for pharma marketers to know: Friday, June 26

Five things for pharma marketers to know: Friday, June 26

Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday

Five things for pharma marketers to know: Wednesday, June 24

Five things for pharma marketers to know: Wednesday, June 24

AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Studies show blood thinner antidotes work

Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.

Five things for pharma marketers to know: Monday, June 22

Five things for pharma marketers to know: Monday, June 22

AstraZeneca, DigitasLBI New York take top prize in pharma category at Cannes Lions Health; Teva buys a stake in Mylan; Shire tops pharma reputation survey.

Grand Prix drought ends, but questions persist

Grand Prix drought ends, but questions persist

The inspirational value is clear for Lions Health attendees, but there is still confusion about what good looks like for branded pharma campaigns, and how the US fits in.

Pharma at Cannes: C'est la Vie

Pharma at Cannes: C'est la Vie

It's not only a venue to gain creative inspiration, but a good place to scout talent, and there are no lack of strategic meetings underway in Cannes.

Novartis exec: Pharma culture can be stumbling block to creativity

Novartis exec: Pharma culture can be stumbling block to creativity

It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.

AstraZeneca wins Pharma Grand Prix at Cannes

AstraZeneca wins Pharma Grand Prix at Cannes

AstraZeneca's "Take it from a Fish" took the top prize.

Five things for pharma marketers to know: Friday, June 19

Five things for pharma marketers to know: Friday, June 19

Teva loses Copaxone patent suit; Oncologists at Memorial Sloan Kettering Cancer Center developed cancer drug cost calculator; Bayer will invest $4.5 billion in R&D in the coming year.

19 US entries shortlisted at Lions Health

19 US entries shortlisted at Lions Health

The Lions Health award winners will be announced later Friday at an event in Cannes, France.

Doximity expands professional reach

Its alliance with the Society of Hospital Medicine will expand the network's reach among medical professionals.

Takeda revamps commercial org to synch with R&D

Takeda revamps commercial org to synch with R&D

The Japan-based drugmaker recast its global organization in hopes of ensuring that emerging molecules make a smoother transition to market.

EY launches health innovation incubator

The effort is part of the consultancy's Startup Challenge that pairs health neophytes with mentors.

Five things for pharma marketers to know: Thursday, June 18

Five things for pharma marketers to know: Thursday, June 18

Merck settles a marketing lawsuit for $5.9 million; CVS plans to create diagnostic apps; a survey shows advertising agencies plan to keep head count steady for the rest of the year

Lilly moves to bolster its oncology pipeline

Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute signed on to help the drugmaker develop cancer treatments.

Drug pricing drives debates at BIO convention

Drug pricing drives debates at BIO convention

Drugmakers, experts discuss strategies to cope with costly new drugs.

Five things for pharma marketers to know: Wednesday, June 17

Five things for pharma marketers to know: Wednesday, June 17

Allergan acquires double-chin treatment manufacturer, Kythera, for $2.1 billion; Valeant eyes acquisition of Egyptian drugmaker; worldwide drug sales could reach $1 trillion by 2020

Study shows pharma compensates genders differently

Study shows pharma compensates genders differently

A dive into financial relationships between industry and doctors showed women receive less money for research, education and speaking than men.

Clinton tells pharma to explain drug prices

Clinton tells pharma to explain drug prices

Speakers at Klick Health's event criticized, lauded the role of technology in healthcare.

Bayer and Johns Hopkins University ink eye-disease research collaboration

The drugmaker and university will work together to develop new treatments for eye-related diseases like age-related macular degeneration.

Five things for pharma marketers to know: Tuesday, June 16

Five things for pharma marketers to know: Tuesday, June 16

Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs

Amicus briefs pile up in Amarin lawsuit

The Medical Information Working Group and the Washington Legal Foundation filed briefs in support of Amarin.

Survey shows doctors ready for PCSK9s

Survey shows doctors ready for PCSK9s

Cardiologists are more likely to prescribe the experimental drugs than are primary-care physicians.

Five things for pharma marketers to know: Monday, June 15

Five things for pharma marketers to know: Monday, June 15

CVS Health to buy Target's pharmacy business; experimental gene therapy improves condition of teen with sickle-cell disease; PatientsLikeMe partners with the FDA to improve postmarket surveillance

Five things for pharma marketers to know: Friday, June 12

Five things for pharma marketers to know: Friday, June 12

PhRMA files amicus brief in support of Amarin's off-label lawsuit; Public Citizen argues FDA wrongly expanded indication for Hetlioz; FDA panel recommends GSK's new asthma treatment for approval

Amarin lawsuit about more than fish oil

Amarin lawsuit about more than fish oil

An FDA letter says there was no need to go to court but experts tell MM&M this lawsuit highlights an issue that is bigger than a single pill.

Public health officials to distribute Truvada in fight against HIV

Los Angeles County voted in favor of adding the drug to the public health program's repertoire in fighting HIV and AIDS.

Five things for pharma marketers to know: Thursday, June 11

Five things for pharma marketers to know: Thursday, June 11

Amgen's PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire's hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups

Pioneering info portal for doctors turns 20

Pioneering info portal for doctors turns 20

Medscape marked its 20th anniversary with a reunion this week that attracted staffers from the portal's earliest days.

Pfizer's "Get Old" campaign gets youthful

Pfizer's "Get Old" campaign gets youthful

The three-year-old campaign's youthful tone evolves as its audience ages.

Roche sclerosis drug granted Breakthrough Therapy status

Roche's Actemra is already approved for three forms of arthritis.

Five things for pharma marketers to know: Wednesday, June 10

Five things for pharma marketers to know: Wednesday, June 10

FDA panel recommends Sanofi/Regeneron's PCSK9 inhibitor for approval; Merck and Samsung collaboration says their rheumatoid arthritis biosimilars are equivalent to the biologic versions; Bayer offloads its diabetes-care business

Study: 10 medications will cost US $50 billion over 10 years

Study: 10 medications will cost US $50 billion over 10 years

An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.

Lions Health entries increase by 30% in 2015

A quarter of this year's 1,862 entries are in the pharma category.

GSK asthma medication to go before FDA panel Thursday

GSK asthma medication to go before FDA panel Thursday

There has been little talk about mepolizumab but an approval would fill out GSK's flagging respiratory category.

Sanofi will resubmit lixisenatide to FDA

The drugmaker's once-daily diabetes treatment, lixisenatide, will be sent back to US regulators after Sanofi pulled the submission in 2013 to finish a cardiovascular outcomes trial.

Five things for pharma marketers to know: Tuesday, June 9

Five things for pharma marketers to know: Tuesday, June 9

Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids

PCSK9 adcomm preview: what's at stake

PCSK9 adcomm preview: what's at stake

An FDA advisory committee will sound off on the future of cholesterol-lowering treatments this week, discussing if Sanofi/Regeneron's Praluent and Amgen's Repatha warrant marketing approval.

Everyday Health names new EVP

Jed Savage replaces Scott Wolf.

Lilly says peglispro is superior to Sanofi's Lantus

Concerns persist regarding the drug's impact on liver enzymes and fat.

Five things for pharma marketers to know: Monday, June 8

Five things for pharma marketers to know: Monday, June 8

Novartis CEO says pharma must regulate itself; Shire reportedly is in talks to buy biotech Actelion; Lilly insulin outperforms Lantus although safety concerns remain

Five things for pharma marketers to know: Friday, June 5

Five things for pharma marketers to know: Friday, June 5

FDA panel recommends approval of female Viagra; FDA says that Sanofi's and Regeneron's PCSK9 inhibitor lowers LDL; GSK cuts 350 jobs

DTC expected to propel Afrezza awareness, not necessarily sales

DTC expected to propel Afrezza awareness, not necessarily sales

Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.

A Patient Journey Isn't the Solution to Pharma Marketing—It's the Beginning

A Patient Journey Isn't the Solution to Pharma Marketing—It's the Beginning

We need to view the patient journey as a starting place for much deeper analysis.

FDA grants Breakthrough status to Niemann-Pick drug

Genzyme's experimental enzyme-replacement therapy olipudase alfa is being investigated for the Type B form of the condition.

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Study: Patients with marketplace health plans spend less on medications

Study: Patients with marketplace health plans spend less on medications

Employer-insured enrollees spend more on prescriptions than health-insurance exchange enrollees, but the groups spend the same amount of money when it comes to specialty medications, a study shows.

Five things for pharma marketers to know: Wednesday, June 3

Five things for pharma marketers to know: Wednesday, June 3

Teva is planning to up its stake in Mylan prior to a possible legal challenge; Perrigo acquires GSK OTC portfolio; Express Scripts considers creative ways to drive down drug costs

Patient advocacy groups say pharma needs to be a better partner

Patient advocacy groups say pharma needs to be a better partner

An inVentiv Health study indicates patient groups want more say in drug development and patient support.

Five things for pharma marketers to know: Tuesday, June 2

Five things for pharma marketers to know: Tuesday, June 2

A House committee is looking into the FDA's warning letter publication process; Amgen and Roche collaborate on cancer combination drug; study shows online health information fails teenagers

GSK's Flonase tops allergy category

The new OTC medication almost hit $100 million in sales in its first 16 weeks on the market.

Cannes Grand Prix may again prove elusive for pharma

Cannes Grand Prix may again prove elusive for pharma

The Lions Health jurors in 2014 declined to award the top prize in the pharma category, raising questions about how the industry's creativity stacks up against the world's top marketers.

A Q&A with Rob Rogers, 2015 Lions Health pharma jury president

A Q&A with Rob Rogers, 2015 Lions Health pharma jury president

He spoke with MM&M about whether pharma is ready to win a Grand Prix, if regulation limits creativity in healthcare, and why wearables may spur creativity.

In their words: the most inspirational speakers at the 2014 Lions Health

An MM&M roundup of what the festival's most inspirational speakers had to say about creativity in healthcare and challenges like talent recruitment and implementing digital innovation.

Five things for pharma marketers to know: Monday, June 1

Five things for pharma marketers to know: Monday, June 1

Bristol-Myers Squibb's Opdivo serves up lukewarm lung-cancer results; new cancer drugs are too expensive, Sloan Kettering oncologist tells ASCO attendees; Teva settlement could stymie industry use of pay-for-delay patent tactics

Five things for pharma marketers to know: Friday, May 29

Five things for pharma marketers to know: Friday, May 29

Amgen prepares for pricing battle over PCSK9-inhibitor Repatha; Otsuka loses Abilify lawsuit; healthcare and pharma marketers will boost spending on digital advertising in 2015

Five things for pharma marketers to know: Thursday, May 28

Five things for pharma marketers to know: Thursday, May 28

The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate

Express Scripts wants cancer drugs to prove value

Express Scripts wants cancer drugs to prove value

The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.

Roche diagnostic unit partnering with drugmaker on companion diagnostic

The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.

Five things for pharma marketers to know: Wednesday, May 27

Five things for pharma marketers to know: Wednesday, May 27

Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill

NPs expand right to practice independently

Twenty states now allow nurse practitioners to practice without an MD affiliation.

ASCO preview: What's coming for lung cancer

ASCO preview: What's coming for lung cancer

A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.

J&J puts global media business up for review

J&J puts global media business up for review

The review does not include North America, the healthcare giant said.

Five things for pharma marketers to know: Tuesday, May 26

Five things for pharma marketers to know: Tuesday, May 26

Experimental psoriasis drug linked to suicidal thoughts; analysis finds that some high prescribers receive non-research industry money; researchers say new MS drugs spur higher prices of older medications

Five things for pharma marketers to know: Friday, May 22

Five things for pharma marketers to know: Friday, May 22

Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression

OPDP finds fault with Rapaflo website

The FDA's advertising division said images and copy for the BPH drug Rapaflo are misleading.

Five things for pharma marketers to know: Thursday, May 21

Five things for pharma marketers to know: Thursday, May 21

CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year

Banner triggers OPDP letter to Oak Pharmaceuticals

The FDA's bad-ad group said the banner they saw at a professional conference was misleading.

Torres: Career challenges prepared her to take reins at McNeil

Torres: Career challenges prepared her to take reins at McNeil

McNeil Consumer Healthcare president Denice Torres was named woman of the year by the Healthcare Businesswomen's Association.

Five things for pharma marketers to know: Tuesday, May 19

Five things for pharma marketers to know: Tuesday, May 19

Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition

Makovsky's head of health moving to Finn Partners

Makovsky's head of health moving to Finn Partners

Long-time practice lead Gil Bashe is tasked with unifying and building the health function at global firm Finn Partners.

Five things for pharma marketers to know: Friday, May 15

Five things for pharma marketers to know: Friday, May 15

Genentech alums launch a new biotechnology company; Mallinckrodt sues the FDA over a drug reclassification; Sanofi takes on celiac disease

Contrave dispute causes co-marketer tension

Contrave dispute causes co-marketer tension

An expert tells MM&M a key issue is whether unsubstantiated benefits were used in marketing efforts.

Study: Diagnostics not keeping pace with personalized medicine

Study: Diagnostics not keeping pace with personalized medicine

Precision medicine is a guiding force for many pipelines, but a study shows a gap between developing drugs with biomarkers as well as tests that match patients to treatments.

Five things for pharma marketers to know: Thursday, May 14

Five things for pharma marketers to know: Thursday, May 14

An economist wants $37 billion invested in antibiotic development; Roche plans to file an experimental lung-cancer drug with the FDA this year; Sandoz wants compensation for lost Zarxio sales

Five things for pharma marketers to know: Wednesday, May 13

Five things for pharma marketers to know: Wednesday, May 13

FDA panel votes in favor of Vertex's combination cystic fibrosis drug; MannKind blames marketing on slow Afrezza sales; Orexigen draws ire after Contrave study terminated

HHS says Namenda switch could cost $6 billion

The government agency said discontinuing Namenda IR before generic competition enters the market could cost Medicare and its beneficiaries billions over the next decade.

Strategies to Increase the Value of Drug Therapy

Strategies to Increase the Value of Drug Therapy

Value is a concept that concerns all healthcare stakeholders.

Weight-loss drug prescriptions rise ... slowly

Weight-loss drug prescriptions rise ... slowly

First-quarter results show prescription weight-loss drugs continue to struggle with market and mind share.

Five things for pharma marketers to know: Tuesday, May 12

Five things for pharma marketers to know: Tuesday, May 12

Mylan considers higher bid for Perrigo; Boehringer Ingelheim partners with health system on COPD; EMD Serono's experimental cancer drug gets Fast Track status

FDA panel to review Vertex CF combo therapy on Tuesday

FDA panel to review Vertex CF combo therapy on Tuesday

While the FDA is not required to follow the panel's recommendation, the agency's final decision on Orkambi is crucial to Vertex's future.

Actavis to pursue development of eye drug

Molecular Partners said development for its experimental wet age-related macular degeneration treatment will go forward.

Five things for pharma marketers to know: Monday, May 11

Five things for pharma marketers to know: Monday, May 11

Mylan weighs Teva takeover; GSK and UNC launch research center and drug company; FDA approves Roche colorectal cancer drug diagnostic

Apple Watch Changes the Health Wearables Game

Apple Watch Changes the Health Wearables Game

An early review of the Apple Watch

Five things for pharma marketers to know: Thursday, May 7

Five things for pharma marketers to know: Thursday, May 7

A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug

Sanofi/Regeneron eczema drug could have limited competition

Sanofi/Regeneron eczema drug could have limited competition

About 80% of polled dermatologists told Leerink Partners they would likely prescribe the experimental biologic dupilumab.

Pharma M&A activity reaches new heights this year

Pharma M&A activity reaches new heights this year

Spurred by consolidation, the life sciences industry spent more money on acquisitions in the first quarter than it did in all of 2014 combined.

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.